keyword
MENU ▼
Read by QxMD icon Read
search

Lithium bipolar

keyword
https://www.readbyqxmd.com/read/28654858/reference-values-of-lithium-in-postmortem-femoral-blood
#1
Carl Söderberg, Emma Wernvik, Anna K Jönsson, Henrik Druid
INTRODUCTION: The main recipients of lithium, people diagnosed with bipolar disorder, show an increased mortality in both natural and unnatural causes of death. Based on international data persons diagnosed with bipolar disorder comprise 2.3-9.6% of all suicidal deaths. In cases of suicide among those suffering from bipolar disorder, 17-53% are due to fatal intoxications. Diagnosing fatal intoxications is often challenging, particularly when the reference information needed to interpret the concentration of a drug is lacking or scarce...
June 15, 2017: Forensic Science International
https://www.readbyqxmd.com/read/28651936/efficacy-safety-and-tolerability-of-aripiprazole-in-bipolar-disorder-an-updated-systematic-review-and-meta-analysis-of-randomized-controlled-trials
#2
Dian-Jeng Li, Ping-Tao Tseng, Brendon Stubbs, Che-Sheng Chu, Han-Yung Chang, Eduard Vieta, Michele Fornaro, Andre F Carvalho, Marco Solmi, Nicola Veronese, Tien-Yu Chen, Yen-Wen Chen, Pao-Yen Lin, Philip Chik-Keung Chow
Numerous studies have investigated aripiprazole as a treatment for bipolar disorder (BD). therefore we conducted this comprehensive meta-analysis to investigate the efficacy and safety profile of aripiprazole in treating BD. Two authors conducted systematic searches of PubMed and ScienceDirect from inception until May 14th, 2017. Randomized controlled trials (RCTs) of people with BD who received aripiprazole were included. A total of 20 RCTs met the eligibility criteria, including two which investigated the efficacy of aripiprazole versus haloperidol (aripiprazole=340; haloperidol=337), three which compared aripiprazole versus lithium (aripiprazole=208; lithium=212), and 15 with multiple comparisons of aripiprazole versus a placebo (aripiprazole=1923; placebo=1499)...
June 23, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28647815/update-on-the-epidemiology-diagnosis-and-treatment-of-mania-in-older-age-bipolar-disorder
#3
REVIEW
Peijun Chen, Annemiek Dols, Soham Rej, Martha Sajatovic
PURPOSE OF REVIEW: The population over age 60 is growing more rapidly than the general population. Given the projected increase and need for data that can inform treatment, this review provides a brief description of newer publications focused on mania in older-age bipolar disorder (OABD), including epidemiology, diagnosis, and treatments. RECENT FINDINGS: Age cutoffs to define OABD range from 50 to 65 years. OABD clinical presentation and course of illness is highly variable, often characterized by mood episode recurrence, medical comorbidity, cognitive deficits, and impaired functioning...
August 2017: Current Psychiatry Reports
https://www.readbyqxmd.com/read/28641149/thyroid-autoimmunity-in-bipolar-disorder-a-systematic-review
#4
REVIEW
Margherita Barbuti, André F Carvalho, Cristiano A Köhler, Andrea Murru, Norma Verdolini, Giovanni Guiso, Ludovic Samalin, Michael Maes, Brendon Stubbs, Giulio Perugi, Eduard Vieta, Isabella Pacchiarotti
BACKGROUND: Accumulating evidence points to the pathophysiological relevance between immune dysfunction and mood disorders. High rates of thyroid dysfunction have been found in patients with bipolar disorder (BD), compared to the general population. A systematic review of the relationship between BD and thyroid autoimmunity was performed. METHODS: Pubmed, EMBASE and PsycINFO databases were searched up till January 28th, 2017. This review has been conducted according to the PRISMA statements...
June 13, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28639153/genomics-of-lithium-action-and-response
#5
REVIEW
Benjamin S Pickard
Lithium is the most successful mood stabilizer treatment for bipolar disorder. However, unlike conventional drugs that are designed to interact with a specific molecular target, the actions of lithium are distributed across many biological processes and pathways. Treatment response is subject to genetic variation between individuals and similar genetic variation may dictate susceptibility to side effects. Transcriptomic, genomic, and cell-model research strategies have all been deployed in the search for the genetic factors and biological systems that mediate the interaction between genetics and the therapeutic actions of lithium...
June 21, 2017: Neurotherapeutics: the Journal of the American Society for Experimental NeuroTherapeutics
https://www.readbyqxmd.com/read/28631584/clinical-characterization-of-italian-suicide-attempters-with-bipolar-disorder
#6
Bernardo Dell'Osso, Matteo Vismara, Cristina Dobrea, Laura Cremaschi, Benedetta Grancini, Chiara Arici, Beatrice Benatti, Massimiliano Buoli, Terence A Ketter, A Carlo Altamura
Introduction Bipolar disorder (BD) is a chronic, highly disabling condition associated with psychiatric/medical comorbidity and substantive morbidity, mortality, and suicide risks. In prior reports, varying parameters have been associated with suicide risk. OBJECTIVES: To evaluate sociodemographic and clinical variables characterizing Italian individuals with BD with versus without prior suicide attempt (PSA). METHODS: A sample of 362 Italian patients categorized as BD according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM IV-TR) was assessed and divided in 2 subgroups: with and without PSA...
June 20, 2017: CNS Spectrums
https://www.readbyqxmd.com/read/28629296/atypical-antipsychotic-use-and-outcomes-in-an-urban-maternal-mental-health-service
#7
Susan Hatters Friedman, Charmian Moller-Olsen, Chandni Prakash, Abigail North
Objective Despite many women suffering from psychosis in their childbearing years, limited data exist about the use of atypical antipsychotic agents in pregnancy. Atypical antipsychotic agents are often used to treat bipolar disorder, instead of lithium or valproate because of the known teratogenicity of those agents. As well, atypical antipsychotics are often prescribed in anxiety disorders and depression. This study sought to describe pregnancy outcomes for women prescribed atypical antipsychotics during pregnancy...
August 2016: International Journal of Psychiatry in Medicine
https://www.readbyqxmd.com/read/28628769/complex-psychotropic-polypharmacy-in-bipolar-disorder-across-varying-mood-polarities-a-prospective-cohort-study-of-2712-inpatients
#8
Julia C Golden, John W Goethe, Stephen B Woolley
BACKGROUND: It is common for patients with bipolar disorder (BP) to receive multiple psychotropics, but few studies have assessed demographic and clinical features associated with risk for receiving complex psychotropic polypharmacy. METHODS: This longitudinal cohort study examined 2712 inpatients with a DSM-IV clinical diagnosis of BP to assess associations between complex polypharmacy (defined as ≥4 psychotropics) and demographic and clinical features; associations with risk of rehospitalization were also examined...
June 13, 2017: Journal of Affective Disorders
https://www.readbyqxmd.com/read/28625858/stem-cells-pluripotency-and-glial-cell-markers-in-peripheral-blood-of-bipolar-patients-on-long-term-lithium-treatment
#9
REVIEW
Ewa Ferensztajn-Rochowiak, Jolanta Kucharska-Mazur, Maciej Tarnowski, Jerzy Samochowiec, Mariusz Z Ratajczak, Janusz K Rybakowski
BACKGROUND: We investigated the effect of long-term lithium treatment on very-small embryonic-like stem cells (VSELs) and the mRNA expression of pluripotency and glial markers, in peripheral blood, in patients with bipolar disorder (BD). METHODS: Fifteen BD patients (aged 53±7years) not treated with lithium, with duration of illness >10years, 15 BD patients (aged 55±6years) treated with lithium for 8-40years (mean 16years) and 15 control subjects (aged 50±5years) were included...
June 15, 2017: Progress in Neuro-psychopharmacology & Biological Psychiatry
https://www.readbyqxmd.com/read/28622205/effect-of-excessive-coffee-consumption-on-the-clinical-course-of-a-patient-with-bipolar-disorder-a-case-report-and-literature-review
#10
Yutaka Kunitake, Yoshito Mizoguchi, Rintaro Sogawa, Jun Matsushima, Takahiro A Kato, Toshiro Kawashima, Akira Monji
OBJECTIVE: The aim of this study was to examine the impact of excessive caffeine consumption on therapeutic outcomes in bipolar disorder. METHODS AND RESULTS: We report on a case of a patient with bipolar disorder whose psychiatric symptoms were ameliorated with the elevation of lithium concentrations after the reduction of excessive daily coffee consumption, and we review the relevant literatures. CONCLUSIONS: Excessive coffee consumption may exacerbate the therapeutic course of bipolar disorder through its effects on the mechanisms underlying bipolar disorder itself, as well as by affecting the blood concentration of lithium...
June 16, 2017: Clinical Neuropharmacology
https://www.readbyqxmd.com/read/28621662/chronic-lithium-treatment-elicits-its-antimanic-effects-via-bdnf-trkb-dependent-synaptic-downscaling
#11
Erinn S Gideons, Pei-Yi Lin, Melissa Mahgoub, Ege T Kavalali, Lisa M Monteggia
Lithium is widely used as a treatment for Bipolar Disorder although the molecular mechanisms that underlie its therapeutic effects are under debate. In this study, we show brain-derived neurotrophic factor (BDNF) is required for the antimanic-like effects of lithium but not the antidepressant-like effects in mice. We performed whole cell patch clamp recordings of hippocampal neurons to determine the impact of lithium on synaptic transmission that may underlie the behavioral effects. Lithium produced a significant decrease in α-amino-3-hydroxyl-5-methyl-4-isoxazolepropionic acid receptor (AMPAR)-mediated miniature excitatory postsynaptic current (mEPSC) amplitudes due to postsynaptic homeostatic plasticity that was dependent on BDNF and its receptor tropomyosin receptor kinase B (TrkB)...
June 16, 2017: ELife
https://www.readbyqxmd.com/read/28621334/telomere-length-and-bipolar-disorder
#12
Timothy R Powell, Danai Dima, Sophia Frangou, Gerome Breen
Variation in telomere length is heritable and is currently considered a promising biomarker of susceptibility for neuropsychiatric disorders, particularly because of its association with memory function and hippocampal morphology. Here, we investigate telomere length in connection to familial risk and disease expression in bipolar disorder (BD). We used quantitative polymerase chain reactions and a telomere-sequence to single-copy-gene-sequence ratio method to determine telomere length in genomic DNA extracted from buccal smears from 63 patients with BD, 74 first-degree relatives (49 relatives had no lifetime psychopathology and 25 had a non-BD mood disorder) and 80 unrelated healthy individuals...
June 16, 2017: Neuropsychopharmacology: Official Publication of the American College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/28617434/lispro-mitigates-%C3%AE-amyloid-and-associated-pathologies-in-alzheimer-s-mice
#13
Ahsan Habib, Darrell Sawmiller, Song Li, Yang Xiang, David Rongo, Jun Tian, Huayan Hou, Jin Zeng, Adam Smith, Shengnuo Fan, Brian Giunta, Takashi Mori, Glenn Currier, Douglas Ronald Shytle, Jun Tan
Lithium has been marketed in the United States of America since the 1970s as a treatment for bipolar disorder. More recently, studies have shown that lithium can improve cognitive decline associated with Alzheimer's disease (AD). However, the current United States Food and Drug Administration-approved lithium pharmaceutics (carbonate and citrate chemical forms) have a narrow therapeutic window and unstable pharmacokinetics that, without careful monitoring, can cause serious adverse effects. Here, we investigated the safety profile, pharmacokinetics, and therapeutic efficacy of LISPRO (ionic co-crystal of lithium salicylate and l-proline), lithium salicylate, and lithium carbonate (Li2CO3)...
June 15, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28616776/evidence-towards-rna-binding-motif-rnp1-rrm-protein-3-rbm3-as-a-potential-biomarker-of-lithium-response-in-bipolar-disorder-patients
#14
Eleni Merkouri Papadima, Paola Niola, Carla Melis, Claudia Pisanu, Donatella Congiu, Cristiana Cruceanu, Juan Pablo Lopez, Gustavo Turecki, Raffaella Ardau, Giovanni Severino, Caterina Chillotti, Maria Del Zompo, Alessio Squassina
Lithium has been used for more than six decades for the management of bipolar disorder (BD). In a previous transcriptomic study, we showed that patients affected by either BD or cluster headache, both disorders characterized by circadian disturbances and response to lithium in a subgroup of patients, have higher expression of the RNA binding motif (RNP1, RRM) protein 3 (RBM3) gene compared to controls. To investigate whether RBM3 could represent a biomarker of lithium response, we screened raw microarray expression data from lymphoblastoid cell lines (LCLs) derived from 20 BD patients, responders or non-responders to lithium...
June 14, 2017: Journal of Molecular Neuroscience: MN
https://www.readbyqxmd.com/read/28615247/lithium-induced-ndi-acetazolamide-reduces-polyuria-but-does-not-improve-urine-concentrating-ability
#15
Theun de Groot, Joan Doornebal, Birgitte M Christensen, Simone C Cockx, Anne P Sinke, Ruben Baumgarten, Jennifer J Bedford, Robert J Walker, Jack F Wetzels, Peter M T Deen
Lithium is the mainstay treatment for patients with bipolar disorder, but generally causes nephrogenic diabetes insipidus (NDI), a disorder in which the renal urine concentrating ability has become vasopressin-insensitive. Li-NDI is caused by lithium uptake by collecting duct principal cells and downregulation of AQP2 water channels, which are essential for water uptake from pro-urine. Recently, we found that the prophylactic administration of acetazolamide to mice effectively attenuated Li-NDI. To evaluate whether acetazolamide might benefit lithium-treated patients, we administered acetazolamide to mice with established Li-NDI and six patients with a lithium-induced urinary concentrating defect...
June 14, 2017: American Journal of Physiology. Renal Physiology
https://www.readbyqxmd.com/read/28595491/suicidal-behavior-during-lithium-and-valproate-treatment-a-within-individual-8-year-prospective-study-of-50-000-patients-with-bipolar-disorder
#16
Jie Song, Arvid Sjölander, Erik Joas, Sarah E Bergen, Bo Runeson, Henrik Larsson, Mikael Landén, Paul Lichtenstein
OBJECTIVE: Conclusions regarding lithium's antisuicidal effect for bipolar disorder have been limited due to nonrepresentative subjects and potential confounding factors, including varying severity of illness. Findings regarding the effect of valproate, the most common alternative to lithium, are inconsistent for suicidal behavior. This study investigated the associations of these two drugs with the risk of suicide-related events, and possible differences between drugs, by using within-individual designs in a register-based longitudinal cohort...
June 9, 2017: American Journal of Psychiatry
https://www.readbyqxmd.com/read/28593454/permanent-cerebellar-degeneration-after-acute-hyperthermia-with-non-toxic-lithium-levels-a-case-report-and-review-of-literature
#17
REVIEW
Fabian H Rossi, Elisa Marie Rossi, Michael Hoffmann, Welwin Liu, Ramon Rodriguez Cruz, Natasha Antonovich, Arash Rezaei, Elizabeth Gonzalez, Maria Clara Franco, Alvaro Estevez, Florian Thomas
This was a study of a 33-year-old man with bipolar disorder treated with lithium who developed cerebellar atrophy after an event of extreme hyperthermia. Unlike previously reported cases of acute cerebellar atrophy after heat stroke, neuroleptic syndrome or lithium toxicity, this case was characterized by a chronic cerebellar atrophy that developed after sepsis-induced hyperthermia in the setting of non-toxic lithium levels. Unique to this case also was the early finding of cerebellar atrophy on MRI 2 weeks after the episode of hyperthermia, long-term neurotoxicity after the novo lithium therapy, and longest follow-up case of chronic cerebellar syndrome after hyperthermia with non-toxic lithium levels...
June 8, 2017: Cerebellum
https://www.readbyqxmd.com/read/28578901/pharmacological-treatments-and-risk-of-readmission-to-hospital-for-unipolar-depression-in-finland-a-nationwide-cohort-study
#18
Jari Tiihonen, Antti Tanskanen, Fabian Hoti, Pia Vattulainen, Heidi Taipale, Juha Mehtälä, Markku Lähteenvuo
BACKGROUND: Little is known about the comparative effectiveness of long-term pharmacological treatments for severe unipolar depression. We aimed to study the effectiveness of pharmacological treatments in relapse prevention in a nationwide cohort of patients who had been admitted to hospital at least once as a result of unipolar depression. METHODS: Our nationwide cohort study investigated the risk of readmission to hospital in 1996-2012 in all patients in Finland who had been admitted to hospital at least once for unipolar depression (without a diagnosis of schizophrenia or bipolar disorder) in Finland between Jan 1, 1987, and Dec 31, 2012...
June 1, 2017: Lancet Psychiatry
https://www.readbyqxmd.com/read/28576914/do-not-treat-the-numbers-lithium-toxicity
#19
Peter Foulser, Yasmin Abbasi, Anand Mathilakath, Ramin Nilforooshan
We describe the case of a 62-year-old man with a history of bipolar disorder, previously stable on lithium for over 20 years, who presented with a manic relapse and signs of lithium toxicity in the form of a coarse tremor. Serum lithium levels were in the normal range, and the patient had stage 3 chronic kidney disease. He was admitted for treatment under Section 2 of the Mental Health Act, and after stopping lithium was started on olanzapine. Signs of lithium toxicity improved after withdrawal of lithium. This case highlights the need to treat normal serum lithium levels with caution in patients showing signs of clinical lithium toxicity...
June 2, 2017: BMJ Case Reports
https://www.readbyqxmd.com/read/28575066/combined-application-of-arsenic-trioxide-and-lithium-chloride-augments-viability-reduction-and-apoptosis-induction-in-human-rhabdomyosarcoma-cell-lines
#20
Sabine B Schleicher, Julian J Zaborski, Rosa Riester, Natascha Zenkner, Rupert Handgretinger, Torsten Kluba, Frank Traub, Karen A Boehme
Rhabdomyosarcomas (RMS) are the most prevalent soft tissue sarcomas affecting children and adolescents. Despite intensive treatment consisting of multimodal chemotherapy and surgery RMS patients diagnosed with metastatic disease expect long term survival rates of only 20%. Often multidrug resistance arises upon initial response emphasizing the need for new therapeutic drugs to improve treatment efficiency. Previously, we demonstrated the efficacy of the FDA approved drug arsenic trioxide (ATO) specifically inhibiting viability and clonal growth as well as inducing cell death in human RMS cell lines of different subtypes...
2017: PloS One
keyword
keyword
69613
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"